Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corporation on March 15, 2018. The filing addresses Item 5.02 regarding the approval of annual base salaries and incentive awards for executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments effective for Fiscal Year 2018.
Material Changes
The Compensation Committee approved the following changes to executive compensation, effective January 1, 2018, for base salaries and March 15, 2018, for equity awards:
- Phillip P. Chan, MD, PhD (CEO): Base salary increased to $400,000 (approx. 5.8% increase). Awarded stock options valued at $117,750 and 10,300 Change in Control Restricted Stock Units (RSUs).
- Vincent J. Capponi (COO): Base salary increased to $332,000 (approx. 5.7% increase). Awarded stock options valued at $110,350 and 10,100 Change in Control RSUs.
- Kathleen P. Bloch (CFO): Base salary increased to $295,000 (approx. 7.3% increase). Awarded stock options valued at $93,500 and 8,800 Change in Control RSUs.
- Eric R. Mortensen (CMO): Base salary increased to $339,000 (approx. 2.7% increase). Awarded stock options valued at $80,000 and 20,000 Change in Control RSUs.
All stock options have a strike price of $7.90 and a 10-year term. Vesting is contingent upon specific performance milestones including budgeted revenues, regulatory approvals, and strategic partnerships.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The vesting of stock options is tied to the achievement of 2018 budgeted revenues, operating expense targets, regulatory approvals, and new strategic partnerships, as determined by the Board.
Investor Verification Checklist
- Verify the specific performance metrics defined by the Board for the 35% revenue/expense vesting milestone.
- Confirm the regulatory approval and clinical trial objectives required for the 32.5% vesting milestone.
- Review the definition of "Change In Control" in the 2014 Long-Term Incentive Plan regarding the RSU settlement.
- Monitor the company's ability to meet the 2018 budgeted revenue targets to trigger option vesting.